CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 1 - 10 of 897
Study Number Lead Group Study Title CIRB Study Status
S1512 SWOG A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM) Adult CIRB - Late Phase Emphasis Available to Open
E1910 ECOG A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults Adult CIRB - Late Phase Emphasis Available to Open
EAA172 ECOG-ACRIN Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone with or without Venetoclax in Relapsed/Refractory Multiple Myeloma with Assessment for t(11;14) Status Adult CIRB - Late Phase Emphasis Completed
NSABP-B-51 NSABP A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Adult CIRB - Late Phase Emphasis Available to Open
A071801 Alliance Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease Adult CIRB - Late Phase Emphasis Available to Open
GOG-0209 GOG Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer Adult CIRB - Late Phase Emphasis Available to Open
S1007 SWOG A Phase III; Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes; Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node; Endocrine Responsive Breast Cancer Adult CIRB - Late Phase Emphasis Available to Open
A041501 Alliance A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL Adult CIRB - Late Phase Emphasis Available to Open
E2906 ECOG Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy; Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years) Adult CIRB - Late Phase Emphasis Available to Open
A041703 Alliance Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease Adult CIRB - Late Phase Emphasis Available to Open
Displaying 1 - 10 of 897